
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is well-positioned for growth and success in the healthcare industry due to their diverse portfolio, successful new product launches, and strong performance in their Innovative Medicine division. With a focus on key therapeutic areas and strategic plans for continued growth, JNJ has the potential to become a top oncology company by 2030 and continue to expand through M&A and innovation. However, potential risks such as new product launches and macro issues should be closely monitored. Additionally, JNJ's long history and presence in critical therapeutic areas make them a stable and reliable investment choice.
Bears say
Johnson & Johnson is facing several challenges that may impact its future growth potential and financial performance. These include potential difficulties in its pharmaceutical pipeline gaining traction, the risk of losing patent exclusivity for certain drugs, and ongoing legal disputes related to its talc products. Additionally, the recent divestment of its consumer business may result in slower growth as it focuses solely on healthcare. These concerns, along with a potential decline in sales from its MedTech division, contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares